Clinical Trial Update: OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of OSI-774 (gefitinib) with cisplatin and docetaxel in head and neck squamous cell carcinoma; results have been posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• OSI-774 (gefitinib) (gefitinib)
• Taxotere (docetaxel) (docetaxel)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Head and Neck Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-15